APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Unfractionated Heparin

Compare research editions
View pricing & licenses

Selected research

Industry Research

Unfractionated Heparin Industry Research Report 2026

Report ID 174044420523 December 2025150 pages

Choose your research edition.

Industry ResearchUnfractionated Heparin Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Unfractionated Heparin Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Unfractionated Heparin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Unfractionated Heparin Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Unfractionated Heparin Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Unfractionated Heparin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Unfractionated Heparin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Unfractionated Heparin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Unfractionated Heparin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Unfractionated Heparin include Shenzhen Techdow Pharmaceutical, Sanofi, Mylan, Jianyou Pharmaceutical, Pfizer, Dongcheng Pharmaceutical, Changshan Pharma, B. Braun and Wellona Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Unfractionated Heparin market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Unfractionated Heparin Market by Company

Shenzhen Techdow Pharmaceutical

Sanofi

Mylan

Jianyou Pharmaceutical

Pfizer

Dongcheng Pharmaceutical

Changshan Pharma

B. Braun

Wellona Pharma

Troikaa Pharmaceuticals

Stanex

Sagent Pharmaceuticals, Inc

Rotexmedica GmbH

Rewine Pharmaceutical

Panpharma

Organon Canada

Leo Pharma

Gland Pharma Limited

Bioiberica

Bharat Serums and Vaccines

Unfractionated Heparin Segment by Type

Heparin Sodium

Heparin Calcium

Unfractionated Heparin Segment by Application

Unstable Angina

Pulmonary Embolism (PE)

Deep Vein Thrombosis (DVT)

Atrial Fibrillation-related Clots

Myocardial Infarction

Other

Unfractionated Heparin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Unfractionated Heparin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Unfractionated Heparin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Unfractionated Heparin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Unfractionated Heparin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Unfractionated Heparin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Unfractionated Heparin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Unfractionated Heparin Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Unfractionated Heparin Sales (k units) of Manufacturers (2021-2026) Table 7. Global Unfractionated Heparin Sales Market Share by Manufacturers (2021-2026) Table 8. Global Unfractionated Heparin Revenue of Manufacturers (2021-2026) Table 9. Global Unfractionated Heparin Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Unfractionated Heparin Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Unfractionated Heparin Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Unfractionated Heparin, Product Type & Application Table 14. Global Unfractionated Heparin Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Unfractionated Heparin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Shenzhen Techdow Pharmaceutical Company Information Table 19. Shenzhen Techdow Pharmaceutical Business Overview Table 20. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolio Table 22. Shenzhen Techdow Pharmaceutical Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Sanofi Unfractionated Heparin Product Portfolio Table 27. Sanofi Recent Developments Table 28. Mylan Company Information Table 29. Mylan Business Overview Table 30. Mylan Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Mylan Unfractionated Heparin Product Portfolio Table 32. Mylan Recent Developments Table 33. Jianyou Pharmaceutical Company Information Table 34. Jianyou Pharmaceutical Business Overview Table 35. Jianyou Pharmaceutical Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Jianyou Pharmaceutical Unfractionated Heparin Product Portfolio Table 37. Jianyou Pharmaceutical Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Pfizer Unfractionated Heparin Product Portfolio Table 42. Pfizer Recent Developments Table 43. Dongcheng Pharmaceutical Company Information Table 44. Dongcheng Pharmaceutical Business Overview Table 45. Dongcheng Pharmaceutical Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolio Table 47. Dongcheng Pharmaceutical Recent Developments Table 48. Changshan Pharma Company Information Table 49. Changshan Pharma Business Overview Table 50. Changshan Pharma Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Changshan Pharma Unfractionated Heparin Product Portfolio Table 52. Changshan Pharma Recent Developments Table 53. B. Braun Company Information Table 54. B. Braun Business Overview Table 55. B. Braun Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. B. Braun Unfractionated Heparin Product Portfolio Table 57. B. Braun Recent Developments Table 58. Wellona Pharma Company Information Table 59. Wellona Pharma Business Overview Table 60. Wellona Pharma Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Wellona Pharma Unfractionated Heparin Product Portfolio Table 62. Wellona Pharma Recent Developments Table 63. Troikaa Pharmaceuticals Company Information Table 64. Troikaa Pharmaceuticals Business Overview Table 65. Troikaa Pharmaceuticals Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolio Table 67. Troikaa Pharmaceuticals Recent Developments Table 68. Stanex Company Information Table 69. Stanex Business Overview Table 70. Stanex Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Stanex Unfractionated Heparin Product Portfolio Table 72. Stanex Recent Developments Table 73. Sagent Pharmaceuticals, Inc Company Information Table 74. Sagent Pharmaceuticals, Inc Business Overview Table 75. Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolio Table 77. Sagent Pharmaceuticals, Inc Recent Developments Table 78. Rotexmedica GmbH Company Information Table 79. Rotexmedica GmbH Business Overview Table 80. Rotexmedica GmbH Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Rotexmedica GmbH Unfractionated Heparin Product Portfolio Table 82. Rotexmedica GmbH Recent Developments Table 83. Rewine Pharmaceutical Company Information Table 84. Rewine Pharmaceutical Business Overview Table 85. Rewine Pharmaceutical Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Rewine Pharmaceutical Unfractionated Heparin Product Portfolio Table 87. Rewine Pharmaceutical Recent Developments Table 88. Panpharma Company Information Table 89. Panpharma Business Overview Table 90. Panpharma Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Panpharma Unfractionated Heparin Product Portfolio Table 92. Panpharma Recent Developments Table 93. Organon Canada Company Information Table 94. Organon Canada Business Overview Table 95. Organon Canada Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Organon Canada Unfractionated Heparin Product Portfolio Table 97. Organon Canada Recent Developments Table 98. Leo Pharma Company Information Table 99. Leo Pharma Business Overview Table 100. Leo Pharma Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Leo Pharma Unfractionated Heparin Product Portfolio Table 102. Leo Pharma Recent Developments Table 103. Gland Pharma Limited Company Information Table 104. Gland Pharma Limited Business Overview Table 105. Gland Pharma Limited Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Gland Pharma Limited Unfractionated Heparin Product Portfolio Table 107. Gland Pharma Limited Recent Developments Table 108. Bioiberica Company Information Table 109. Bioiberica Business Overview Table 110. Bioiberica Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Bioiberica Unfractionated Heparin Product Portfolio Table 112. Bioiberica Recent Developments Table 113. Bharat Serums and Vaccines Company Information Table 114. Bharat Serums and Vaccines Business Overview Table 115. Bharat Serums and Vaccines Unfractionated Heparin Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Bharat Serums and Vaccines Unfractionated Heparin Product Portfolio Table 117. Bharat Serums and Vaccines Recent Developments Table 118. Global Unfractionated Heparin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Unfractionated Heparin Sales by Region (2021-2026) & (k units) Table 120. Global Unfractionated Heparin Sales Market Share by Region (2021-2026) Table 121. Global Unfractionated Heparin Sales by Region (2027-2032) & (k units) Table 122. Global Unfractionated Heparin Sales Market Share by Region (2027-2032) Table 123. Global Unfractionated Heparin Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Unfractionated Heparin Revenue Market Share by Region (2021-2026) Table 125. Global Unfractionated Heparin Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Unfractionated Heparin Revenue Market Share by Region (2027-2032) Table 127. North America Unfractionated Heparin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 129. North America Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 130. North America Unfractionated Heparin Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Unfractionated Heparin Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Unfractionated Heparin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 134. Europe Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 135. Europe Unfractionated Heparin Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Unfractionated Heparin Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Unfractionated Heparin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 139. Asia Pacific Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 140. Asia Pacific Unfractionated Heparin Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Unfractionated Heparin Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Unfractionated Heparin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 144. South America Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 145. South America Unfractionated Heparin Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Unfractionated Heparin Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Unfractionated Heparin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 149. Middle East and Africa Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 150. Middle East and Africa Unfractionated Heparin Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Unfractionated Heparin Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Unfractionated Heparin Sales by Type (2021-2026) & (k units) Table 153. Global Unfractionated Heparin Sales by Type (2027-2032) & (k units) Table 154. Global Unfractionated Heparin Sales Market Share by Type (2021-2026) Table 155. Global Unfractionated Heparin Sales Market Share by Type (2027-2032) Table 156. Global Unfractionated Heparin Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Unfractionated Heparin Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Unfractionated Heparin Revenue Market Share by Type (2021-2026) Table 159. Global Unfractionated Heparin Revenue Market Share by Type (2027-2032) Table 160. Global Unfractionated Heparin Price by Type (2021-2026) & (USD/unit) Table 161. Global Unfractionated Heparin Price by Type (2027-2032) & (USD/unit) Table 162. Global Unfractionated Heparin Sales by Application (2021-2026) & (k units) Table 163. Global Unfractionated Heparin Sales by Application (2027-2032) & (k units) Table 164. Global Unfractionated Heparin Sales Market Share by Application (2021-2026) Table 165. Global Unfractionated Heparin Sales Market Share by Application (2027-2032) Table 166. Global Unfractionated Heparin Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Unfractionated Heparin Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Unfractionated Heparin Revenue Market Share by Application (2021-2026) Table 169. Global Unfractionated Heparin Revenue Market Share by Application (2027-2032) Table 170. Global Unfractionated Heparin Price by Application (2021-2026) & (USD/unit) Table 171. Global Unfractionated Heparin Price by Application (2027-2032) & (USD/unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Unfractionated Heparin Distributors List Table 175. Unfractionated Heparin Customers List Table 176. Unfractionated Heparin Industry Trends Table 177. Unfractionated Heparin Industry Drivers Table 178. Unfractionated Heparin Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Unfractionated Heparin Product Image Figure 5. Global Unfractionated Heparin Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Unfractionated Heparin Market Size (2021-2032) & (US$ Million) Figure 7. Global Unfractionated Heparin Sales (2021-2032) & (k units) Figure 8. Global Unfractionated Heparin Average Price (USD/unit) & (2021-2032) Figure 9. Heparin Sodium Product Image Figure 10. Heparin Calcium Product Image Figure 11. Unstable Angina Product Image Figure 12. Pulmonary Embolism (PE) Product Image Figure 13. Deep Vein Thrombosis (DVT) Product Image Figure 14. Atrial Fibrillation-related Clots Product Image Figure 15. Myocardial Infarction Product Image Figure 16. Other Product Image Figure 17. Global Unfractionated Heparin Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Unfractionated Heparin Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Unfractionated Heparin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Unfractionated Heparin Sales by Region in 2025 Figure 23. Global Unfractionated Heparin Revenue by Region in 2025 Figure 24. North America Unfractionated Heparin Market Size by Country in 2025 Figure 25. North America Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 26. North America Unfractionated Heparin Revenue Market Share by Country (2021-2032) Figure 27. United States Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Unfractionated Heparin Market Size by Country in 2025 Figure 31. Europe Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 32. Europe Unfractionated Heparin Revenue Market Share by Country (2021-2032) Figure 33. Germany Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Unfractionated Heparin Market Size by Country in 2025 Figure 44. Asia Pacific Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Unfractionated Heparin Revenue Market Share by Country (2021-2032) Figure 46. China Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Unfractionated Heparin Market Size by Country in 2025 Figure 55. South America Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 56. South America Unfractionated Heparin Revenue Market Share by Country (2021-2032) Figure 57. Brazil Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Unfractionated Heparin Market Size by Country in 2025 Figure 61. Middle East and Africa Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Unfractionated Heparin Revenue Market Share by Country (2021-2032) Figure 63. Egypt Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Unfractionated Heparin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Unfractionated Heparin Sales Market Share by Type (2021-2032) Figure 69. Global Unfractionated Heparin Revenue Market Share by Type (2021-2032) Figure 70. Global Unfractionated Heparin Price (USD/unit) by Type (2021-2032) Figure 71. Global Unfractionated Heparin Sales Market Share by Application (2021-2032) Figure 72. Global Unfractionated Heparin Revenue Market Share by Application (2021-2032) Figure 73. Global Unfractionated Heparin Price (USD/unit) by Application (2021-2032) Figure 74. Unfractionated Heparin Value Chain Figure 75. Unfractionated Heparin Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Unfractionated Heparin Industry Opportunities and Challenges

Scope & coverage.

Types
  • Heparin Sodium
  • Heparin Calcium
Applications
  • Unstable Angina
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation-related Clots
  • Myocardial Infarction
  • Other
Companies covered
  • Shenzhen Techdow Pharmaceutical
  • Sanofi
  • Mylan
  • Jianyou Pharmaceutical
  • Pfizer
  • Dongcheng Pharmaceutical
  • Changshan Pharma
  • B. Braun
  • Wellona Pharma
  • Troikaa Pharmaceuticals
  • Stanex
  • Sagent Pharmaceuticals, Inc
  • Rotexmedica GmbH
  • Rewine Pharmaceutical
  • Panpharma
  • Organon Canada
  • Leo Pharma
  • Gland Pharma Limited
  • Bioiberica
  • Bharat Serums and Vaccines

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Unfractionated Heparin Market Size (2021-2032)
  4. 2.2.2 Global Unfractionated Heparin Sales (2021-2032)
  5. 2.2.3 Global Unfractionated Heparin Market Average Price (2021-2032)
  6. 2.3 Unfractionated Heparin by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Heparin Sodium
  9. 2.3.3 Heparin Calcium
  10. 2.4 Unfractionated Heparin by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Unstable Angina
  13. 2.4.3 Pulmonary Embolism (PE)
  14. 2.4.4 Deep Vein Thrombosis (DVT)
  15. 2.4.5 Atrial Fibrillation-related Clots
  16. 2.4.6 Myocardial Infarction
  17. 2.4.7 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Unfractionated Heparin Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Unfractionated Heparin Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Unfractionated Heparin Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Unfractionated Heparin Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Unfractionated Heparin Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Unfractionated Heparin, Product Type & Application
  8. 3.8 Global Manufacturers of Unfractionated Heparin, Established Date
  9. 3.9 Global Unfractionated Heparin Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Shenzhen Techdow Pharmaceutical
  2. 4.1.1 Shenzhen Techdow Pharmaceutical Company Information
  3. 4.1.2 Shenzhen Techdow Pharmaceutical Business Overview
  4. 4.1.3 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolio
  6. 4.1.5 Shenzhen Techdow Pharmaceutical Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Unfractionated Heparin Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Mylan
  14. 4.3.1 Mylan Company Information
  15. 4.3.2 Mylan Business Overview
  16. 4.3.3 Mylan Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Mylan Unfractionated Heparin Product Portfolio
  18. 4.3.5 Mylan Recent Developments
  19. 4.4 Jianyou Pharmaceutical
  20. 4.4.1 Jianyou Pharmaceutical Company Information
  21. 4.4.2 Jianyou Pharmaceutical Business Overview
  22. 4.4.3 Jianyou Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Jianyou Pharmaceutical Unfractionated Heparin Product Portfolio
  24. 4.4.5 Jianyou Pharmaceutical Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer Unfractionated Heparin Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 Dongcheng Pharmaceutical
  32. 4.6.1 Dongcheng Pharmaceutical Company Information
  33. 4.6.2 Dongcheng Pharmaceutical Business Overview
  34. 4.6.3 Dongcheng Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolio
  36. 4.6.5 Dongcheng Pharmaceutical Recent Developments
  37. 4.7 Changshan Pharma
  38. 4.7.1 Changshan Pharma Company Information
  39. 4.7.2 Changshan Pharma Business Overview
  40. 4.7.3 Changshan Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Changshan Pharma Unfractionated Heparin Product Portfolio
  42. 4.7.5 Changshan Pharma Recent Developments
  43. 4.8 B. Braun
  44. 4.8.1 B. Braun Company Information
  45. 4.8.2 B. Braun Business Overview
  46. 4.8.3 B. Braun Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 B. Braun Unfractionated Heparin Product Portfolio
  48. 4.8.5 B. Braun Recent Developments
  49. 4.9 Wellona Pharma
  50. 4.9.1 Wellona Pharma Company Information
  51. 4.9.2 Wellona Pharma Business Overview
  52. 4.9.3 Wellona Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Wellona Pharma Unfractionated Heparin Product Portfolio
  54. 4.9.5 Wellona Pharma Recent Developments
  55. 4.10 Troikaa Pharmaceuticals
  56. 4.10.1 Troikaa Pharmaceuticals Company Information
  57. 4.10.2 Troikaa Pharmaceuticals Business Overview
  58. 4.10.3 Troikaa Pharmaceuticals Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolio
  60. 4.10.5 Troikaa Pharmaceuticals Recent Developments
  61. 4.11 Stanex
  62. 4.11.1 Stanex Company Information
  63. 4.11.2 Stanex Business Overview
  64. 4.11.3 Stanex Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Stanex Unfractionated Heparin Product Portfolio
  66. 4.11.5 Stanex Recent Developments
  67. 4.12 Sagent Pharmaceuticals, Inc
  68. 4.12.1 Sagent Pharmaceuticals, Inc Company Information
  69. 4.12.2 Sagent Pharmaceuticals, Inc Business Overview
  70. 4.12.3 Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolio
  72. 4.12.5 Sagent Pharmaceuticals, Inc Recent Developments
  73. 4.13 Rotexmedica GmbH
  74. 4.13.1 Rotexmedica GmbH Company Information
  75. 4.13.2 Rotexmedica GmbH Business Overview
  76. 4.13.3 Rotexmedica GmbH Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Rotexmedica GmbH Unfractionated Heparin Product Portfolio
  78. 4.13.5 Rotexmedica GmbH Recent Developments
  79. 4.14 Rewine Pharmaceutical
  80. 4.14.1 Rewine Pharmaceutical Company Information
  81. 4.14.2 Rewine Pharmaceutical Business Overview
  82. 4.14.3 Rewine Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Rewine Pharmaceutical Unfractionated Heparin Product Portfolio
  84. 4.14.5 Rewine Pharmaceutical Recent Developments
  85. 4.15 Panpharma
  86. 4.15.1 Panpharma Company Information
  87. 4.15.2 Panpharma Business Overview
  88. 4.15.3 Panpharma Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Panpharma Unfractionated Heparin Product Portfolio
  90. 4.15.5 Panpharma Recent Developments
  91. 4.16 Organon Canada
  92. 4.16.1 Organon Canada Company Information
  93. 4.16.2 Organon Canada Business Overview
  94. 4.16.3 Organon Canada Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Organon Canada Unfractionated Heparin Product Portfolio
  96. 4.16.5 Organon Canada Recent Developments
  97. 4.17 Leo Pharma
  98. 4.17.1 Leo Pharma Company Information
  99. 4.17.2 Leo Pharma Business Overview
  100. 4.17.3 Leo Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Leo Pharma Unfractionated Heparin Product Portfolio
  102. 4.17.5 Leo Pharma Recent Developments
  103. 4.18 Gland Pharma Limited
  104. 4.18.1 Gland Pharma Limited Company Information
  105. 4.18.2 Gland Pharma Limited Business Overview
  106. 4.18.3 Gland Pharma Limited Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Gland Pharma Limited Unfractionated Heparin Product Portfolio
  108. 4.18.5 Gland Pharma Limited Recent Developments
  109. 4.19 Bioiberica
  110. 4.19.1 Bioiberica Company Information
  111. 4.19.2 Bioiberica Business Overview
  112. 4.19.3 Bioiberica Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Bioiberica Unfractionated Heparin Product Portfolio
  114. 4.19.5 Bioiberica Recent Developments
  115. 4.20 Bharat Serums and Vaccines
  116. 4.20.1 Bharat Serums and Vaccines Company Information
  117. 4.20.2 Bharat Serums and Vaccines Business Overview
  118. 4.20.3 Bharat Serums and Vaccines Unfractionated Heparin Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Bharat Serums and Vaccines Unfractionated Heparin Product Portfolio
  120. 4.20.5 Bharat Serums and Vaccines Recent Developments
5 Global Unfractionated Heparin Market Scenario by Region
  1. 5.1 Global Unfractionated Heparin Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Unfractionated Heparin Sales by Region: 2021-2032
  3. 5.2.1 Global Unfractionated Heparin Sales by Region: 2021-2026
  4. 5.2.2 Global Unfractionated Heparin Sales by Region: 2027-2032
  5. 5.3 Global Unfractionated Heparin Revenue by Region: 2021-2032
  6. 5.3.1 Global Unfractionated Heparin Revenue by Region: 2021-2026
  7. 5.3.2 Global Unfractionated Heparin Revenue by Region: 2027-2032
  8. 5.4 North America Unfractionated Heparin Market Facts & Figures by Country
  9. 5.4.1 North America Unfractionated Heparin Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Unfractionated Heparin Sales by Country (2021-2032)
  11. 5.4.3 North America Unfractionated Heparin Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Unfractionated Heparin Market Facts & Figures by Country
  16. 5.5.1 Europe Unfractionated Heparin Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Unfractionated Heparin Sales by Country (2021-2032)
  18. 5.5.3 Europe Unfractionated Heparin Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Unfractionated Heparin Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Unfractionated Heparin Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Unfractionated Heparin Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Unfractionated Heparin Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Unfractionated Heparin Market Facts & Figures by Country
  41. 5.7.1 South America Unfractionated Heparin Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Unfractionated Heparin Sales by Country (2021-2032)
  43. 5.7.3 South America Unfractionated Heparin Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Unfractionated Heparin Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Unfractionated Heparin Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Unfractionated Heparin Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Unfractionated Heparin Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Unfractionated Heparin Sales by Type (2021-2032)
  2. 6.1.1 Global Unfractionated Heparin Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Unfractionated Heparin Sales Market Share by Type (2021-2032)
  4. 6.2 Global Unfractionated Heparin Revenue by Type (2021-2032)
  5. 6.2.1 Global Unfractionated Heparin Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Unfractionated Heparin Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Unfractionated Heparin Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Unfractionated Heparin Sales by Application (2021-2032)
  2. 7.1.1 Global Unfractionated Heparin Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Unfractionated Heparin Sales Market Share by Application (2021-2032)
  4. 7.2 Global Unfractionated Heparin Revenue by Application (2021-2032)
  5. 7.2.1 Global Unfractionated Heparin Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Unfractionated Heparin Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Unfractionated Heparin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Unfractionated Heparin Value Chain Analysis
  2. 8.1.1 Unfractionated Heparin Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Unfractionated Heparin Production Mode & Process
  5. 8.2 Unfractionated Heparin Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Unfractionated Heparin Distributors
  8. 8.2.3 Unfractionated Heparin Customers
9 Global Unfractionated Heparin Analyzing Market Dynamics
  1. 9.1 Unfractionated Heparin Industry Trends
  2. 9.2 Unfractionated Heparin Industry Drivers
  3. 9.3 Unfractionated Heparin Industry Opportunities and Challenges
  4. 9.4 Unfractionated Heparin Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst